HERC2

Across TCGA pan-cancer cohorts, HERC2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated HERC2 data layer compared with 22 for mass-spec protein and 13 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher HERC2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated HERC2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and HNSC show a favorable association.

LUAD, CCRCC, and HNSC are the cancer types where HERC2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	All	0.596	0.833	.002	22	view →
CCRCC	DFS	Tertile	All	0.955	0.698	.004	22	view →
HNSC	OS	Median	II,III,IV	0.835	0.584	.008	11	view →
LSCC	DFS	Tertile	II,III,IV	1.000	0.898	.020	3	view →
GBM	DFS	Median	All	0.867	0.633	.003	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

HERC2–LUAD (DFS)

Open the LUAD breakdown →